AGAmir Ghaderi

Amir Ghaderi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amir Ghaderi has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Crocin Supplementation on Clinical Symptoms, Cognitive Function and Psychological Status in Methamphetamine Users: A Randomized Controlled Trial

    by Morteza Zamani Asadolah-Poor-Kashi, Hamid Reza Banafshe, Mehrdad Simani, Fatemeh Sadat Ghoreishi, Zahra Zanjani, Amir Ghaderi

    Background: Concurrent methamphetamine (METH) use among patients receiving methadone maintenance treatment (MMT) is a growing clinical concern associated with cognitive impairment, psychological distress, and an increased risk of relapse. Crocin (CRO), a bioactive constituent of saffron (Crocus sativus L.), has antioxidant, anti-inflammatory, and neuroprotective properties. Objectives: This study aimed to evaluate the effects of CRO supplementation on withdrawal symptoms, craving, sleep quality, cognitive performance, and psychological status in METH users undergoing MMT. Methods: In this trial, 80 male METH users receiving stable MMT were randomly assigned to CRO (n = 40) or placebo (n = 40) for 8 weeks. All analyses were performed according to the intention-to-treat (ITT) principle and included all 80 randomized participants. The primary outcomes were withdrawal symptoms, assessed with the Amphetamine Withdrawal Questionnaire (AWQ), and craving, measured with the Drug Desire Questionnaire (DDQ). Secondary outcomes were sleep quality (PSQI), sexual function (IIEF), cognitive performance (CAQ), and psychological status (DASS-21). Results: In the ITT analysis (n = 80), CRO significantly reduced withdrawal symptoms (P = 0.036, η2p=0.091) and craving (P = 0.024, η2p=0.110) compared with placebo. Significant improvements were also observed in sleep quality (P = 0.025, η2p=0.103), anxiety (P < 0.008, η2p=0.157), and depression (P = 0.014, η2p=0.126). No significant effects were observed for sexual function, cognitive performance, or stress (P > 0.05). Conclusions: The results of this clinical trial indicate that CRO supplementation, administered as a safe and potentially effective adjunct to MMT, may significantly attenuate withdrawal symptoms, reduce craving intensity, improve sleep quality, and alleviate symptoms of anxiety and depression among individuals with METH use disorder. However, the lack of statistically significant improvements in cognitive performance, sexual function, and perceived stress underscores the multifactorial complexity of these clinical domains and highlights the need for further empirical investigation. It is plausible that cognitive deficits resulting from chronic METH exposure, given their putative neurostructural and neurofunctional underpinnings, may require longer treatment durations or integrative therapeutic strategies. Moreover, sexual dysfunction in this patient population is likely mediated by a confluence of physiological, psychological, and psychosocial factors and, as such, may not be readily ameliorated through antioxidant monotherapy alone.

  • The effect of clavulanic acid on the development of tolerance and dependence induced by morphine in mice: role of DRD2 and NR1 genes, oxidative stress, and GDNF protein

    by Peyman Esmaili-Shahzade-Ali-Akbari, Behrang Alani, Elahe Seyed Hosseini, Hamid Reza Banafshe, Abolfazl Ardjmand, Mohammadreza Rashidi Nooshabadi, Abbas Haghparast, Amir Ghaderi

    Morphine tolerance and dependence are major challenges in opioid addiction treatment. Clavulanic acid (CA), a non-antibiotic β-lactam, has recently garnered attention for its potential neuromodulatory properties. This research was conducted to assess the impact of CA on the induction of tolerance and dependence following morphine administration, as well as to examine its modulatory effects on the gene expression levels of DRD2 and NR1, nitric oxide (NO) and malondialdehyde (MDA) concentrations, and the expression of GDNF protein in the brain of mice. Forty-nine adult male outbred mice (25–30 g) were randomly allocated to seven groups (n = 7). Morphine tolerance/dependence was induced using an escalating subcutaneous regimen for 3 consecutive days (50 mg/kg at 08:00, 50 mg/kg at 12:00, and 75 mg/kg at 16:00). Clavulanic acid (50, 100, or 200 mg/kg), clonidine (0.1 mg/kg; positive control), or normal saline was administered 30 min before each morphine injection. Antinociceptive tolerance was assessed by the tail-flick test following an acute morphine challenge (10 mg/kg, sc) on days 1 and 4. On day 4, locomotor activity was evaluated using the open-field test, and physical dependence was assessed by naloxone-precipitated jumping (5 mg/kg, ip). Brain DRD2 and NR1 mRNA levels were quantified by qRT-PCR; DRD2 and GDNF protein expression was measured by Western blotting, and oxidative stress indices (MDA and NO metabolites) were determined using TBARS and Griess assays, respectively. Repeated morphine administration induced tolerance compared with the control (P < 0.05). Treatment with CA significantly inhibited the development of morphine tolerance at doses of 50 (P < 0.05), 100 (P < 0.01), and 200 mg/kg (P < 0.05) and also suppressed morphine dependence notably at the dose of 200 mg/kg (P < 0.05). Furthermore, administration of CA markedly decreased the relative expression of DRD2 (P < 0.001) and NR1 (P < 0.05) genes and lowered the nitric oxide (NO) levels (P < 0.01) compared to the morphine-treated group. In addition, co-administration of CA significantly increased the expression level of GDNF protein (P < 0.01) in the brain of morphine-treated mice but had no significant effect on the expression level of DRD2 protein compared to the morphine group (P > 0.05). The findings of this study demonstrated that CA markedly attenuates the development of morphine tolerance and dependence. The observed behavioral effects were associated with changes in oxidative stress (NO levels), altered expression of DRD2 and NR1, and increased GDNF expression, suggesting the involvement of multiple interacting pathways.

  • Open Access

    The Efficacy of Spirulina on Cognitive Function, Psychological and Clinical Indicators in Men Patients Under Methadone Therapy (a Randomized Trial)

    by Morteza Zamani Asadolah‐Poor‐Kashi, Peyman Mamsharifi, Freshteh Haerifar, Mehrdad Simani, Amir Ghaderi, Fateme Mehrzad

    Patients undergoing methadone maintenance therapy (MMT) often experience psychological issues and clinical dysfunctions, which can negatively impact the effectiveness of the treatment. Addressing these challenges is crucial for improving patient outcomes. This clinical trials aimed to evaluate the effectiveness of Spirulina (SP) supplementation on craving, psychological distress, sexual performance, and cognitive functions in male receiving methadone. In this double‐blind randomized clinical trial, 50 male patients undergoing MMT were randomly assigned to receive either the SP (500 mg twice daily, n = 25) or the placebo ( n = 25) for 12 weeks. Assessments were conducted at baseline and at the end of the intervention. Psychological indicators were measured using the Depression, Anxiety, and Stress Scale‐21 (DASS‐21); sexual function was evaluated with the International Index for Erectile Function (IIEF); drug craving was assessed via the Drug Desire Questionnaire (DDQ); and cognitive performance was measured with the FAS test, Iowa Gambling Task (IGT), and Trail Making Test (TMT). Overall results support that SP supplementation significantly reduced anxiety and stress score compared to the placebo group ( p < 0.05). However, no significant effects were observed for the depression, sexual function, craving, and cognitive performance measures between the two groups ( p > 0.05). SP supplementation may help alleviate anxiety and stress in men undergoing MMT, suggesting its potential as a supportive intervention. Further studies with larger participant groups are warranted to confirm these effects and explore broader benefits of SP in this population. IRCT Registration: IRCT20231101059923N2 (Registration date: 2023‐12‐16).

  • Open Access

    The effect of probiotics on anxiety, depression, nicotine dependence, and metabolic biomarkers in smokers: a randomized clinical trial

    by Nasim Sadeghi, Shahram Shams, Reyhaneh-Sadat Mirlohian, Freshteh Haerifar, Mostafa Bakhshi-Kashi, Amir Ghaderi

    Cigarette smoking (CS) has long been associated with both metabolic disturbances and psychological dysfunction. Recent evidence suggests that the gut micro

  • Open Access

    A Review of Cardiovascular Diseases in Substance Use Disorders: Current Knowledge and Future Perspectives

    by Fatemeh Zarei, Mehrdad Simani, Hasan Rajabi Moghaddam, Amir Ghaderi

    Background: Nowadays, the emergence of new types of substances and the growing prevalence of addiction have made substance use a global challenge for public health. At the same time, the complications of substance use are observed in various physical and psychological dimensions, including a range of acute and chronic cardiovascular diseases. This issue is significant, as many young people are affected by these complications. Therefore, understanding these complications is both important and practical. Methods: Clinical articles related to the acute and chronic cardiovascular effects of the main groups of substances were searched in the PubMed, Web of Science, Scopus, and Google Scholar databases from 2015 to 2025. Findings: Evidence of cardiovascular complications related to the use of major substance groups, including opioids, stimulants, nicotine, caffeine, alcohol, cannabinoids, tranquilizers, and anabolic steroids, has been obtained. Some of this evidence only indicates an increase in risk factors for the disease, while some reports also point to acute and chronic cardiac complications and even cardiorespiratory arrest and death. Conclusion: Given the cardiac complications of substance use, cessation and treatment should be personalized to each patient’s circumstances.


  • Assessment of Zinc Administration on Metabolic Profile, Oxidative Stress, and Gene Expression in Patients Undergoing Methadone Maintenance Treatment: A Randomized, Double-Blind, Placebo-Controlled Trial

    by Azam Ghaseminejad, Amir Ghaderi, Somayyeh Ghotloo, Hadis Aboutalebian, Hossein Akbari, Esmat Aghadavood, Hamid Reza Banafshe, Nejat Kheiripour

    Background: Methadone maintenance treatment (MMT) causes important clinical problems, such as oxidative stress (OS) and inflammation. Zinc (Zn) has antioxidant and anti-inflammatory effects and regulates gene expression. Objectives: This study investigated the effects of Zn administration on the metabolic, OS, and expression of nuclear factor erythroid 2-related factor 2 (Nrf2), nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ), and interleukin 10 genes in heroin patients undergoing MMT. Methods: This clinical trial was conducted on 45 patients under MMT who received 30 mg/d of Zn (n=23) or placebo (n=22). Fasting blood samples were collected at baseline and 12 weeks after the intervention to quantify metabolic parameters, OS, and gene expression. Results: Zn levels were significantly elevated in the intervention group compared to the placebo group. Further, consuming Zn could significantly improve high-density lipoprotein levels, insulin, homeostasis model assessment-estimated insulin resistance, and OS. Anxiety significantly decreased after 12 weeks of intervention. Finally, Zn up-regulated Nrf2 gene expression in patients under MMT. Conclusion: The results indicated that Zn administration could improve metabolic factors and gene expression in patients undergoing MMT

  • Open Access

    Targeting Internet Addiction Through Body Awareness Psychotherapy: The Mediating Role of Executive Functions and Emotion Regulation

    by Maliheh Fallah, Hamidreza Mohajerani, Abdullah Omidi, Amir Ghaderi

    Background: Internet addiction disorder (IAD) is increasingly recognized as a behavioral addiction linked to deficits in executive functioning, emotion regulation, boredom susceptibility, and impaired time perception. Emerging therapies such as body awareness psychotherapy (BAP) aim to improve cognitive and emotional self‐regulation through embodied mindfulness. This study aimed to assess the effectiveness of BAP in reducing internet addiction and related issues with time perception and boredom, focusing specifically on the mediating roles of executive functions and emotion regulation. Materials and Methods: A randomized controlled trial was conducted with 60 university students (aged 18–30) diagnosed with IAD. Participants were assigned to either the intervention group, which received BAP ( n = 30), or the control group, which participated in general psychological discussions ( n = 30). Over 8 weeks, the BAP group received structured training in body literacy, interoception, and self‐regulation. Assessments included Chen's Internet addiction scale, the multidimensional state boredom scale, the emotion regulation difficulties scale, the time perception task, the Stroop task, and the Iowa gambling task. Mediation analyses were performed using bootstrapped structural equation modeling. Results: BAP significantly reduced levels of internet addiction, boredom, and decision‐making deficits ( p < 0.001). It also improved time perception and executive functions. Mediation analyses confirmed that improvements in executive functions—cognitive flexibility, impulse control, and response inhibition—and emotion regulation, significantly mediated the relationship between BAP and reduced internet addiction ( p < 0.05). Conclusions: BAP is an effective intervention for reducing internet addiction and enhancing executive function and emotional regulation. Its efficacy is mediated by improvements in cognitive function, impulsivity, decision‐making, and emotion regulation, making it a promising tool for addressing behavioral addictions.


  • Open Access

    Evaluation of 10 Years Atherosclerotic Cardiovascular Risk, Vitamin D and Metabolic Profiles in Smokers

    by Mehrdad Simani, Amir Ghaderi, Iman Saffari, Akram Yazdani, Hasan Rajabi Moghaddam, Elaheh Bagherian

    Background: Cardiovascular diseases (CVD) are the primary cause of death and a significant contributor to disability. Atherosclerosis cardiovascular diseases (ASCVD) are responsible for high mortality rates, causing millions of deaths each year. The most important avoidable cause of ASCVD and death is cigarette smoking. This study examined the relationship between 10-year ASCVD in smokers with 25(OH)D and metabolic profiles.Methods: This cross-sectional study was conducted at the Beheshti Hospital in Kashan City, Iran. A total of 144 smokers between the ages of 40 and 75 participated in this study. Addiction and cardiovascular specialists evaluated the patient health questionnaire, and the appropriate tool was used to quantify the 10-year ASCVD risk. Nitric oxide (NO), γ-glutamyl-l-cysteinyl-glycine (GSH), high-sensitivity C-reactive protein (Hs-CRP), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), total antioxidant capacity (TAC) and 25(OH)D were determined, too.Results: About 93% of the 144 participants in this study were men and their mean age was 52.6±8.56 years. The average risk of ASCVD was 10.44±8.72%. Patients’ lifetime and 10-year risk for ASCVD was significantly and negatively correlated with blood 25(OH) D, HDL, GSH, NO and TAC (P<0.05) and positively with TG, LDL, Hs-CRP, smoking duration, and number of cigarettes (P<0.05). Additionally, a negative correlation was seen between the amount of 25(OH)D and the amount of time spent smoking (P<0.05).Conclusion: The results of this study showed that with increased levels of vitamin D, HDL cholesterol, NO, glutathione, and TAC, the risk of developing atherosclerotic CVD was reduced over 10 years. Also, the risk of developing ASCVD over the next 10 years increased with increased levels of TC, LDL-c, TG, Hs-CRP levels and duration and amount of smoking and hypertension.


  • Open Access

    The Role of Orexin Receptor Antagonists in Inhibiting Drug Addiction: A Review Article

    by Peyman Esmaili-Shahzade-Ali-Akbari, Amir - Ghaderi, Atena Sadeghi, Fatemeh Nejat, Alireza Mehramiz

    The orexinergic system and its receptors are involved in many physiological processes. Their functions in energy homeostasis, arousal, cognition, stress processing, endocrine functions, and pain modulation have been investigated. Many studies have shown that the orexinergic system cooperates with the dopaminergic system in the addiction process. Emerging evidence suggests that the orexinergic system can be effective in the induction of drug dependence and tolerance. Therefore, several researches have been conducted on the effect of orexin receptor (OXR) antagonists on reducing tolerance and dependence caused by drug abuse. Due to the significant growth of the studies on the orexinergic system, the current literature was conducted to collect the findings of previous studies on orexin and its receptors in the induction of drug addiction. In addition, cellular and molecular mechanisms of the possible role of orexin in drug tolerance and dependence are discussed. The findings indicate that the administration of OXR antagonists reduces drug dependence. OXR blockers seem to counteract the addictive effects of drugs through multiple mechanisms, such as preventing neuronal adaptation. This review proposes the potential clinical use of OXR antagonists in the treatment of drug dependence.


  • Oral supplementation with crocin (a constituent of saffron) in subjects with cigarette smoking: a clinical trial

    by Mojtaba Mahdavi, Amir Ghaderi, Pooya Hazegh, Mohammad Hassan Karimipour Baseri, Neda Vahed, Shekoofeh Nazemi, Ali Aghajani, Fatemeh Sadat Ghoreishi, Hamidreza Sadeghi-Gandomani, Amene Taghdisi Kashani

    Smoking is one of the main causes of death in the world. Cigarette use is related with various components of metabolic syndrome (e.g., insulin resistance, raised blood pressure, dyslipidemia, oxidative stress, inflammation state) and psychiatric disorders. This study was conducted to determine the effect of crocin (Cro) supplementation on nicotine dependence, anxiety, depression, and metabolic indices in smokers. A total of 50 smokers were selected and randomly categorized into two groups (crocin and placebo). The intervention group received crocin (30 mg per day; n = 25) and placebo (containing Avicel; n = 25) once a day. The primary (nicotine dependence, depression, and anxiety inventory) and secondary (metabolic indices) outcomes were assessed at the start of the intervention and after the 3 months. Multiple linear regression models were used to assess the treatment effects on the outcomes adjusting for confounding variables. The primary outcome results such as nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05). Also in the secondary outcomes, fasting plasma glucose (FPG), insulin, and homeostasis model of assessment-insulin resistance (HOMA-IR) levels did indicate a significant difference by Cro intervention (β − 3.27 mg/dL; 95% CI, − 5.23, − 1.31; P = 0.002; β − 0.76 μIU/mL; 95% CI, − 1.38, − 0.15; P = 0.01; β − 0.18; 95% CI, − 0.29, − 0.07; P = 0.002), respectively. There were also significant reductions in serum levels of high-sensitivity C-reactive protein (hs-CRP) (β − 0.72 mg/L; 95% CI, − 1.37, − 0.07; P = 0.03), compared with the placebo. Cro intake may have favorable effects on the level of FPG, insulin, HOMA-IR, and hs-CRP in smokers. However, due to the small sample size and limited scientific reports on smokers, further studies are necessary. ClinicalTrial.gov Identifier: IRCT20170420033551N11